The Top 6 Corporate Investors In Pharma & Biotech

0

Cytori Therapeutics (NASDAQ: CYTX) has completed its acquisition of Azaya Therapeutics, which will provide Cytori with a proprietary liposomal nanoparticle technology platform and two nanoparticle oncology drugs. The pickup comes with the relatively modest price tag of $4 million, representing the issuance of $2 million in stock and the assumption of approximately $2 million in debt.

For a smaller company like Cytori, a deal in this space hardly comes along every day—indeed, it’s the first acquisition ever for the 21-year-old company. But that’s also because the juiciest targets tend to go to the bigger players in this pricey space. Here are the top six corporate acquirers in the global pharma & biotech industry since the start of 2012:

  1. Allergan (20)
  2. Valeant (17)
  3. Shire (14)
  4. Roche (13)
  5. Pfizer (12)
  6. AstraZeneca (11)

Corporate M&A in pharma & biotech since 2012

Pharma & Biotech

Baupost’s Seth Klarman Suggests That The U.S. Could Be Uninvestable One Day

Seth KlarmanIn his 2021 year-end letter, Baupost's Seth Klarman looked at the year in review and how COVID-19 swept through every part of our lives. He blamed much of the ills of the pandemic on those who choose not to get vaccinated while also expressing a dislike for the social division COVID-19 has caused. Q4 2021 Read More

Since the start of 2012, corporate acquirers have completed 1,417 pharma & biotech transactions, according to the PitchBook Platform. Deal flow in the past five years peaked in 2015 at 388 transactions punctuated by AbbVie’s $21 billion hook up that May with Phamacyclics, a developer of treatments for cancer and immune-mediated inflammatory diseases. At 46% of all deals, the US represents the preponderance of activity in the industry, with the UK a distant second at 7%—Europe overall accounts for 32% of all deals.

PitchBook Platform users can access the full data on corporate investor activity in pharma & biotech.

Not a subscriber? Contact us today to set up a free demo.

Article by Adam Putz, PitchBook

Updated on

No posts to display